Revvity Inc. (RVTY)
NYSE: RVTYIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RVTY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $16.21B
- P/E (TTM)
- 64.54
- Forward P/E
- 24.38
- EPS (TTM)
- $2.25
- Dividend yield
- 0.19% ($0.28)
- Ex-dividend date
- Oct 23, 2026
- 52-week range
- 81.22 – 171.74
- Day range
- 143.61 – 150.40
- Volume / Avg
- 1.66M / 1.91M
- Beta
- —
- Shares outstanding
- 111.64M
52-week range
RVTY stock today
On Nov 20, RVTY ended the session at $145.22, shedding $6.37 (4.20%), versus the S&P 500's 3.70% decline. Shares are 15.4% below their 52-week high of $171.74, set on Nov 3, 2026 and 78.8% above the 52-week low of $81.22, in the middle of the past year's range. RVTY is up 50.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 47.8%.
Revvity trades at 64.5x its trailing twelve-month earnings per share of $2.25. Its forward P/E of 24.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Revvity pays an annual dividend of $0.28 per share, a 0.19% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Revvity
Company profileRevvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Prahlad R. Singh Ph.D.
- Headquarters
- Waltham, MA
- Employees
- 11,000
- Website
- revvity.com
Financial highlights
Full financialsIn fiscal 2025, Revvity generated $2.86 billion in revenue, up 3.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $241.2 million (-10.8% year over year), for a net margin of 8.4% versus a median of 19.2% in the prior 5 years. Operating margin was 12.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B |
| Growth | +3.67% | +0.16% | -16.95% | -13.48% | +1.19% |
| Net income | $241.20M | $270.38M | $693.09M | $569.18M | $943.16M |
| EPS (diluted) | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 |
Analyst forecast
ForecastConsensus (18 analysts)
buy
Avg. price target
$171.40+18.03%
- Strong buy 0
- Buy 6
- Hold 11
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $1.18 vs $1.29
- Surprise
- -8.53%
Dividends
Dividend history- Annual dividend
- $0.28
- Dividend yield
- 0.19%
- Last payment
- $0.07
- Ex-dividend date
- Oct 23, 2026
RVTY news
All RVTY news- Revvity, Inc. (RVTY) Analyst/Investor Day - SlideshowSeeking Alpha
- Revvity, Inc. (RVTY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Revvity, Inc. (RVTY) Analyst/Investor Day TranscriptSeeking Alpha
- ELV or RVTY: Which Is the Better Value Stock Right Now?NasdaqELV, RVTY
- Revvity Consensus Price Target Raised 18.01% to $174.65NasdaqRVTY, BF.A
- All You Need to Know About Revvity (RVTY) Rating Upgrade to BuyNasdaq
- Revvity Q3 Earnings Call HighlightsNasdaq
- Revvity (RVTY) Q3 2026 Earnings Call TranscriptNasdaq
Revvity peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVTRAvantor Inc. | 14.84 | -1.85% | $10.06B | vs RVTY |
| BIOBio-Rad Laboratories Inc. Class A | 358.90 | -2.34% | $9.65B | vs RVTY |
| BRKRBruker Corporation | 56.46 | -9.08% | $8.62B | vs RVTY |
| TXG10x Genomics Inc. Class A | 51.80 | -9.72% | $6.81B | vs RVTY |
| ALMRAlamar Biosciences Inc. | 26.48 | -7.67% | $1.84B | vs RVTY |
| CTKBCytek Biosciences Inc. | 6.12 | -3.16% | $800.40M | vs RVTY |
| PACBPacific Biosciences of California Inc. | 1.63 | -7.39% | $508.95M | vs RVTY |
| NAUTNautilus Biotechnology Inc. | 2.12 | -2.30% | $270.03M | vs RVTY |
Indexes, lists and sector
Index membership
Appears in lists
Revvity stock FAQ
What is Revvity's stock price today?
RVTY last traded at $145.22 as of Nov 20, 4:00 PM EST, down 4.20% on the day. Prices are delayed at least 15 minutes.
Does Revvity pay a dividend?
Yes. Revvity pays $0.28 per share annually, a 0.19% yield. The most recent dividend of $0.07 had an ex-dividend date of Oct 23, 2026.
What is RVTY's P/E ratio?
RVTY trades at a trailing P/E ratio of 64.54 and a forward P/E of 24.38.
Is Revvity in the S&P 500?
Yes. Revvity (RVTY) is a constituent of the S&P 500 index.
Who is Revvity's CEO?
Dr. Prahlad R. Singh Ph.D. is the chief executive officer of Revvity Inc., which has about 11,000 employees.
Has RVTY ever split its stock?
Yes. The most recent RVTY stock split was a 2-for-1 split on Jun 4, 2001, one of 4 splits on record.
What is the RVTY 52-week high?
The 52-week high for RVTY is $171.74 and the 52-week low is $81.22. The stock is currently 15.4% below its high.